Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program
复制标题
DOI：
10.1158/1078-0432.ccr-06-2446
复制
发表时间：
2007-07-01
影响因子：
11.5
通讯作者：
Pirker, Robert
中科院分区：
文献类型：
--
作者：
Filipits, Martin;Haddad, Vincent;Pirker, Robert
目的：本研究的目的是确定多药耐药蛋白（MRP）是否对参加国际辅助肺癌试验（IALT）的患者具有预后和/或预测价值。实验设计：对782例IALT患者的肿瘤标本进行MRP1和MRP2的免疫组织化学检测。预后和预测分析基于经临床和病理变量调整的Cox模型。结果：364例（47%）患者认为MRP1表达阳性，313例（40%）患者认为MRP2表达阳性。mrp2阳性患者在总患者群体中的总生存期明显短于mrp2阴性患者[校正死亡风险比，1.37；95%置信区间（95% CI）， 1.09-1.72；P = 0.007]。MRP1表达与总生存率无显著相关性。MRP1和MRP2均不能预测对以顺铂为基础的辅助化疗的反应。结论：MRP2表达是完全切除的非小细胞肺癌患者的独立预后因素，但MRP1和MRP2在纳入IALT的患者中均不具有预测价值。
Purpose: The purpose of our study was to determine whether multidrug resistance proteins (MRP) are of prognostic and/or predictive value in patients who were enrolled into the International Adjuvant Lung Cancer Trial (IALT).Experimental Design: Expression of MRP1 and MRP2 was immunohistochemically assessed in tumor specimens obtained from 782 IALT patients. Prognostic and predictive analyses were based on Cox models adjusted for clinical and pathologic variables.Results: MRP1 expression was considered positive in 364 (47%) patients and MRP2 expression in 313 (40%) patients. MRP2-positive patients had a significantly shorter overall survival than MRP2-negative patients in the total patient population [adjusted hazard ratio for death, 1.37; 95% confidence interval (95% CI), 1.09-1.72; P = 0.007]. There was no significant association between MRP1 expression and overall survival. Neither MRP1 nor MRP2 predicted response to adjuvant cisplatin-based chemotherapy.Conclusions: MRP2 expression is an independent prognostic factor in patients with completely resected non-small cell lung cancer but neither MRP1 nor MRP2 was of predictive value in patients enrolled into the IALT.